| Male [n (%)] |
68 (75.6%) |
26 (86.7%) |
0.31 |
| Age (years) [median (IQR)] |
47 [39, 52.8] |
45.5 [42, 50.5] |
0.85 |
| Body Mass Index (BMI) (kg/m2) (median [IQR]) |
23 [21.1, 25.7] |
22.8 [21.3, 24.2] |
0.60 |
| Diabetes [n (%)] |
9 (10%) |
1 (3.3%) |
0.45 |
| Duration of HIV infection (years) [median (IQR)] |
12.0 [4.9, 18.3] |
9.7 [4.2, 17.7] |
0.47 |
| CDC disease stage |
|
|
0.20 |
| A |
48 (53.9%) |
20 (66.7%) |
|
| B |
14 (15.7%) |
1 (3.3%) |
|
| C |
27 (30.3%) |
9 (30%) |
|
| Nadir CD4 (cell count, cells/mL) |
204 [112, 297] |
209.5 [67, 313] |
0.79 |
| CD4+ cell count, cells/mL (IQR?) |
492 [344, 657] |
443 [401, 620] |
0.77 |
| Plasma HIV RNA >50 cp/mL [n (%)] |
59 (65.6%) |
1 (3.3%) |
<0.001 |
| Duration of ATV prior to urolithiasis (years) [median (IQR)] |
1.9 [1.2, 3.2] |
3.1 [2.2, 3.8] |
<0.009 |
| Associated ARV therapy [(n) %] |
|
|
|
| Ritonavir (100 mg od) [(n) %] |
68 (75.6%) |
29 (96.7%) |
<0.02 |
| Lamivudine/emtricitabine |
82 (91.1%) |
26 (86.7%) |
0.64 |
| Abacavir |
30 (33.3%) |
10 (33.3%) |
1.00 |
| Zidovudine |
6 (6.7%) |
3 (10%) |
0.69 |
| Didanosine |
11 (12.4%) |
2 (6.7%) |
0.51 |
| Tenofovir |
47 (52.8%) |
16 (53.3%) |
1.00 |
| Baseline creatinine clearance* (median [IQR]) |
91.9 [77.5, 99.9] |
81.5 [73.1, 98.2] |
0.16 |
| Chronic liver disease |
|
|
|
| Hepatitis B |
3 (3.3%) |
1 (0.03%) |
|
| Hepatitis C |
2 (2.2%) |
4 (13.3%) |
|
| Any disease (including hepatitis) |
8 (8.9%) |
6 (20.0%) |
|
| Chronic kidney disease** before urolithiasis [n (%)] |
7 (7.9%) |
4 (14.3%) |
0.29 |
| Prior treatment with indinavir (years) [(n) %] |
18 (20%) |
13 (44.8%) |
<0.02 |
| Duration of indinavir (months) (median [IQR]) |
0 [0, 0] |
0 [0, 32] |
<0.004 |
| Previous history of indinavir-urolithiasis [n (%)] |
1 (1.2%) |
8 (26.7%) |
<0.001 |
| Previous history of urolithiasis before ATV therapy [n (%)] |
7 (7.8%) |
11 (36.7%) |
<0.01 |
| Serum calcium (mmol/L) (median [IQR]) |
2.3 [2.2, 2.4] |
2.3 [2.3, 2.4] |
0.96 |
| Serum free bilirubin level (mmol/L) (median [IQR]) |
30.9 [17.7, 45] |
49.1 [32.5, 56] |
<0.004 |
